Literature DB >> 10505971

Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions.

J Losy1, A Niezgoda, M Wender.   

Abstract

Platelet endothelial cell adhesion molecule, PECAM-1 (CD31) is a 130-kDa glycoprotein, member of the immunoglobulin superfamily, which is involved in transendothelial migration of leukocytes. It is expressed on endothelial cells, lymphocytes, monocytes, neutrophils, basophils and platelets. We present data showing that soluble PECAM-1 is significantly increased in sera of multiple sclerosis patients with active, gadolinium enhancing lesions. Since we have found increased levels of sPECAM-1 in sera of patients with active MRI lesions, but not in those of patients without enhancing lesions, the molecule may be regarded as marker of MS activity. Soluble PECAM-1 may be involved in immunomodulatory mechanism leading to inhibition of migration of leukocytes in MS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10505971     DOI: 10.1016/s0165-5728(99)00092-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

1.  Levels of soluble platelet endothelial cell adhesion molecule-1 and P-selectin are decreased in children with autism spectrum disorder.

Authors:  Charity E Onore; Christine Wu Nordahl; Gregory S Young; Judy A Van de Water; Sally J Rogers; Paul Ashwood
Journal:  Biol Psychiatry       Date:  2012-06-19       Impact factor: 13.382

2.  Endothelial NOS-deficient mice reveal dual roles for nitric oxide during experimental autoimmune encephalomyelitis.

Authors:  Muzhou Wu; Stella E Tsirka
Journal:  Glia       Date:  2009-08-15       Impact factor: 7.452

Review 3.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

4.  Discovery of novel disease-specific and membrane-associated candidate markers in a mouse model of multiple sclerosis.

Authors:  Laura F Dagley; Nathan P Croft; Ruth Isserlin; Jonathan B Olsen; Vincent Fong; Andrew Emili; Anthony W Purcell
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

5.  Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms.

Authors:  Emily K Reinke; Jangeun Lee; Alla Zozulya; Jozsef Karman; William A Muller; Matyas Sandor; Zsuzsanna Fabry
Journal:  J Neuroimmunol       Date:  2007-04-27       Impact factor: 3.478

6.  Wheel running reduces ethanol seeking by increasing neuronal activation and reducing oligodendroglial/neuroinflammatory factors in the medial prefrontal cortex.

Authors:  Sucharita S Somkuwar; McKenzie J Fannon-Pavlich; Atoosa Ghofranian; Jacqueline A Quigley; Rahul R Dutta; Melissa H Galinato; Chitra D Mandyam
Journal:  Brain Behav Immun       Date:  2016-08-16       Impact factor: 7.217

7.  Is MS an inflammatory or primary degenerative disease?

Authors:  Jacek Losy
Journal:  J Neural Transm (Vienna)       Date:  2013-09-06       Impact factor: 3.575

8.  Novel mechanisms of central nervous system damage in HIV infection.

Authors:  Joy E Hazleton; Joan W Berman; Eliseo A Eugenin
Journal:  HIV AIDS (Auckl)       Date:  2010-03-11

9.  PECAM-1 Stabilizes Blood-Brain Barrier Integrity and Favors Paracellular T-Cell Diapedesis Across the Blood-Brain Barrier During Neuroinflammation.

Authors:  Isabella Wimmer; Silvia Tietz; Hideaki Nishihara; Urban Deutsch; Federica Sallusto; Fabien Gosselet; Ruth Lyck; William A Muller; Hans Lassmann; Britta Engelhardt
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

10.  Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function.

Authors:  Beatriz Marcos-Ramiro; Pedro Oliva Nacarino; Esther Serrano-Pertierra; Miguel Angel Blanco-Gelaz; Babette B Weksler; Ignacio A Romero; Pierre O Couraud; Alberto Tuñón; Carlos López-Larrea; Jaime Millán; Eva Cernuda-Morollón
Journal:  BMC Neurosci       Date:  2014-09-22       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.